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1Abstract:
Background: During acute HIV infection (AHI) HIV actively replicates but 
seroconversion has not yet occurred. Primary HIV infection (PHI) is characterized by a 
transient non-specific febrile illness, a massive inflammatory response and the 
progressive appearance of anti-HIV specific antibodies. In this study we have identified
patterns of inflammatory biomarkers associated with the innate immunological 
reaction prior to completion of a full humoral response.
Methods: A symptom-based screening was used to identify AHI in the Manhiça District 
Hospital in Mozambique. Plasma levels of biomarkers were determined by luminex and
ELISA. Anti-HIV antibodies were analysed by flow-cytometry and Western blot. 
Statistical analyses used Random Forest and logistic regression models.
Results: Of 3116 rapid test seronegative or indeterminate individuals, 85 (2.7%) had 
positive plasma HIV viral load and were enrolled as PHI, of which n=45 (52.9%), n=8 
(9.4%), n=12 (14.1%) and n=20 (23.5%) were classified as Fiebig I-III, IV, V and VI stages,
respectively by Western-blot.  Comparison of individuals at early (Fiebig I-IV) and late 
(Fiebig V-VI) immune stages identified significant differences in the expression level of 
plasma BAFF, MCP-1, sCD163 and MIG. This cytokine signature classified patients in the 
pre-seroconversion phase with a sensitivity of 92.5% and a specificity of 81.2%
Conclusions:  Identification of a cytokine signature specific for the pre-seroconversion 
stage of PHI may help to understand the earliest HIV pathogenic events and identify 
new potential targets for immunotherapy aimed at modulating the cytokine response 
to HIV infection.
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Abstract:
Background: During acute HIV infection (AHI) HIV actively replicates but 
seroconversion has not yet occurred. Primary HIV infection (PHI) is characterized by a 
transient non-specific febrile illness, a massive inflammatory response and the 
progressive appearance of anti-HIV specific antibodies. In this study we have identified
patterns of inflammatory biomarkers associated with the innate immunological 
reaction prior to completion of a full humoral response.
Methods: A symptom-based screening was used to identify AHI in the Manhiça District 
Hospital in Mozambique. Plasma levels of biomarkers were determined by luminex and
ELISA. Anti-HIV antibodies were analysed by flow-cytometry and Western blot. 
Statistical analyses used Random Forest and logistic regression models.
Results: Of 3116 rapid test seronegative or indeterminate individuals, 85 (2.7%) had 
positive plasma HIV viral load and were enrolled as PHI, of which n=45 (52.9%), n=8 
(9.4%), n=12 (14.1%) and n=20 (23.5%) were classified as Fiebig I-III, IV, V and VI stages,
respectively by Western-blot.  Comparison of individuals at early (Fiebig I-IV) and late 
(Fiebig V-VI) immune stages identified significant differences in the expression level of 
plasma BAFF, MCP-1, sCD163 and MIG. This cytokine signature classified patients in the 
pre-seroconversion phase with a sensitivity of 92.5% and a specificity of 81.2%
Conclusions:  Identification of a cytokine signature specific for the pre-seroconversion
stage of PHI may help to understand the earliest HIV pathogenic events and identify 
new potential targets for immunotherapy aimed at modulating the cytokine response 
to HIV infection.
3MAIN TEXT
Introduction
Acute HIV infection (AHI) is commonly defined as the period between the HIV 
transmission event and the development of an antibody response to HIV antigens  
defined as seroconversion
1
. Recent infection generally is considered the phase up to 6 
months after infection during which anti-HIV-1 antibodies are detectable. Throughout 
this article, the term primary HIV infection (PHI) is used to refer to both acute and 
recent HIV-1 infection
2
.
AHI is characterised by high HIV viral replication, massive gut-associated 
lymphoid tissue (GALT) CD4+ T cell destruction, immune activation and the 
establishment of viral reservoirs
3
. As a result of high viraemia in bodily fluids and high 
levels of genital viral shedding, individuals are considered hyper-infectious at this 
stage
4,5
. Current HIV antibody tests typically become positive within 3–6 weeks of 
infection and 1–3 weeks after the onset of acute HIV symptoms
6
. This seronegative
window is thus of crucial importance for early treatment outcome, vaccine 
development and public health
7,8
. 
Despite the importance of AHI, there are immense difficulties identifying AHI 
patients for treatment initiation. Patients are often asymptomatic, or experience a non-
specific febrile illness; a diagnostic dilemma compounded in the African setting by a 
significant symptom overlap with malaria
9,10
. To diagnose AHI, the presence of the virus 
itself must be detected by nucleic acids or proteins in the absence of HIV-specific 
4antibodies. Fourth-generation HIV assays have demonstrated good sensitivity and 
specificity for detecting HIV infection and AHI but remain less sensitive than nucleic 
acid amplification technology
11
. Thus, current gold-standard test for confirming 
viraemia is RT-PCR for plasma HIV RNA
12
, while the most widely accepted assay for 
confirmation of HIV antibody testing is Western Blot (WB) or indirect 
immunofluorescence assay (IFA)
13
.
PHI is a rapidly evolving phase characterized by the stepwise gain in positivity for 
the detection of HIV RNA and HIV-specific antibodies. Different HIV-1 antigen 
specificities appear in sequence after HIV-1 transmission as do immunoglobulin G (IgG) 
subclass responses
3
. As such, using different diagnostic tools, PHI has been categorised 
into ‘Fiebig stages’
14
 that are useful in approximating infection date with relative 
accuracy
15
.
As HIV viraemia increases, there is a striking cascade response of acute phase 
reactants and inflammatory cytokines which has been referred to as the ‘cytokine 
storm’
3
. Although many of the cytokines present are common inflammatory pathway 
effectors, their study can shed light on key pathogenic pathways occurring prior to the
generation of the humoral response
16–20
. We hypothesize that the expression patterns 
of these early response cytokines may be different between pre and post-
seroconversion stages of the PHI phase. These effectors could provide clues for vaccine 
or immunomodulator development aimed at reducing the irreversible immune damage 
inflicted during AHI.
5Methods
Study population
The study population was enrolled between 2013 and 2014 at the Manhiça
District Hospital (MDH) in the district of Manhiça, Southern Mozambique. The present 
analysis is a sub-study of a prospective cohort of primary HIV infected adults enrolled 
and followed up for 12 months in the study of gastrointestinal inflammation (GAMA 
cohort). This study was approved by local institutional review boards at Barcelona Clinic 
Hospital (2011/6264) and by the Ministry of Health of Mozambique (461/CNBS/12). 
Written informed consent was obtained from patients prior to participation. 
Adults over 18 years of age, who were residents of the established District 
Surveillance System (DSS) study area, and who presented to the outpatient clinic of the 
MDH for non-specific febrile symptoms or voluntary HIV counselling and testing (VCT) 
were invited to participate in the study.
HIV diagnosis
Blood was collected via finger-prick for HIV rapid antibody testing with Determine 
HIV 1/2 (Abbott Laboratories, Chicago, IL). Positive results were then confirmed with a 
more specific Unigold rapid test (Trinity Biotech Co., Wicklow, Ireland) following the 
national guidelines. Individuals with a positive HIV serology in both rapid tests were 
referred for clinical management and were not eligible for enrolment into the study. 
Primary HIV infection was diagnosed in patients with a negative or indeterminate rapid 
test serology (first test negative or first test positive and second test negative) and 
positive HIV viremia by  RT-PCR testing on frozen plasma using Abbott Real Time HIV-1 
assay (Illinois, U.S.) according to manufacturer’s instructions, with a sensitivity of 
6detection of 150 copies/ml. . HIV-RNA was quantified by applying a multi–level pooling 
scheme of 10 samples/pool as described and validated in previous work 
21
. A subgroup 
of HIV-negative time-matched controls was selected via computer randomisation.
Clinical follow-up
Individuals identified with PHI and the control subgroup of HIV-negative
individuals were invited to attend a study visit 1 month after the screening date to start 
the follow up in the context of the GAMA cohort. In this paper, the 1 month visit 
sample was only employed to establish the reference level for the biomarkers in a non-
febrile non-HIV infected group and the coinfections and CD4 and CD8 T-cell counts in 
both study groups. Demographic and clinical data was collected in a specific 
questionnaire. Medical consultation and HIV counselling was provided. CD4 and CD8 T 
cell counts were determined using CD3, CD8, CD4 and CD45 fluorochrome-labelled 
antibodies on fresh whole blood in a single platform system using Trucount tubes (BD 
Biosciences, New Jersey, U.S.). Clinical and microbiological evaluation was performed, 
testing for the most prevalent infections in the area. 
Quantification of immunoglobulins and definition of primary HIV infection 
phases (see Detailed Methodology section in the Supplementary data).
HIV specific antibodies present in plasma screening samples were assessed by 
Western Blot assay (WB) for sg-p120, gp41, p31, p24, p17 antigens and sgp105 and 
gp36 antigens for HIV type 2 infection using INNO-LIA™ HIV I/II Score (Innogenetics
N.V. Gent, Belgium). Patients with a negative or indeterminate WB result were 
considered to be in the pre-serconversion acute stage and patients with a positive WB 
result were considered to be in the post-seroconversion recent stage of HIV infection.
7Thus, in our study cohort seropositive status was defined as positive WB result at
screening. Viral Load (VL) and WB results at screening visit were employed to 
categorize individuals into Fiebig stages I-III (VL positive, WB negative), IV (VL positive, 
WB indeterminate), V (VL positive, WB positive with p31 band negative), VI (VL positive, 
WB positive with p31 band positive) according to previous work
14
. 
Seven plasma antibody isotypes (IgA, IgM, IgG1, IgG2, IgG3, IgG4 and total IgG) 
were quantified in the screening samples by an in house ELISA. HIV specific antibodies 
of different subtypes (IgG1, IgG2, IgG3, IgG4) for HIV antigens (gp41-Env, p24-Gag and 
p31-integrase) were performed by multi-parametric flow cytometry.
Quantification of plasma cytokines (see Detailed Methodology section in the 
Supplementary data).Multiplex cytokine profiling was performed for a total of 54 
cytokines in screening plasma samples with particular interest in biomarkers of 
intestinal damage (10 biomarkers), T, B and monocyte cells function (23 biomarkers) 
and general biomarkers of inflammation and cell death (21 biomarkers)
(Supplementary table 1). Determinations were performed by ELISA assay or Luminex
multi-analyte profiling technology. 
Statistical analysis
Group comparisons by Fiebig stage were performed using the non-parametric 
Kruskal-Wallis test and Chi-squared test for categorical variables. Multiple tests were 
adjusted using the Bonferroni correction.  Post hoc pairwise comparisons between 
Fiebig stages were performed by Dunn’s test with Bonferroni adjustment. Comparisons 
between PHI and non-HIV infected controls were based on the non-parametric Mann-
Whitney U-test. Identification of cytokines with the best performance in distinguishing 
8between pre- and post-seroconversion stages was performed using Random Forest 
analysis. Random forest is a supervised learning method based on the ensemble of 
multiple classification trees 
22
.  Relation between early and late Fiebig stages with 
respect the selected cytokines were explored by Principal Component Analysis (PCA). 
Patterns of the selected cytokines by PHI phases was assessed by multivariate logistic 
regression. Outcome was a binary variable where 1 represents pre-seroconversion AHI 
group (Fiebig I-IV) and 0 represents recent HIV infected group (Fiebig V-VI).  In both 
PCA and regression model, MIG, MCP-1 and BAFF values were log transformed for a 
better adjustment of the data. Clinical variables (age, gender, VL and other co-
infection) were tested for inclusion in the model by backward step-wise elimination 
approach (inclusion criteria was p-value<0.05 in multivariate analysis). Statistical 
analyses were performed using R-3.2.2 and Stata14 software.
Results
Identification of primary HIV infected individuals
Among the 4011 outpatients screened at the MDH, 3000 (74.8%) presented with 
fever-like symptoms and 1011 (25.2%) for voluntary HIV testing. Seven hundred and 
ninety-nine (20%) were seropositive on rapid testing, and a further 92 (2.3%) were 
excluded prior to serological testing, mainly due to residence outside of the study area 
(Figure 1). A majority (64.4%) of screened patients were under the age of 30, and most 
(62.8%) were female. These age and gender tendencies were similar between 
seropositive patients and those subjects who met criteria for inclusion in the study 
(data not shown).
9Of the 3116 rapid test seronegative or indeterminate patients who entered 
pyramid pooling for HIV RNA testing, 87.1% were individuals presented for non-specific 
febrile symptoms. Ninety-three had a detectable level of HIV-RNA and 4 patients were 
excluded for presenting an inconclusive HIV-RNA result. Eight of these rapid test-
seronegative HIV-RNA-positive cases were found to be positive for antibodies against 
all the HIV antigens by subsequent Western Blot testing and excluded (Figure 1). Eighty-
five individuals thus fulfilled criteria for PHI; a prevalence of 2.73% (95% confidence 
interval 2.18-3.36) among all enrolled patients, and 3.02% (95% confidence interval 
2.41-3.74)  among those who were symptomatic at presentation.
Characteristics of the primary HIV infected population
At the screening visit, the median age of PHI cases was 24 years (IQR 20-30), 58% 
were female and most (96%) presented with a non-specific febrile syndrome to the 
outpatient ward including reported fever, flu or headache (Table 1). There was no 
significant difference in age, gender balance or malaria co-infection between the 85 PHI 
cases and the 3019 HIV-negative subjects. PHI cases reported a significantly greater 
total number of symptoms than did HIV-negative patients, and were significantly more 
likely to report fever in the last 24 hours (p-value=0.024), and intestinal complaint 
(diarrhoea or abdominal pain) in the last week (p-value<0.001). Fifty-six PHI cases 
(70%) returned to commence follow-up and n=58 HIV-negative participants were 
randomly selected to attend the 1 month follow-up visit as a reference group. There 
was no significant difference in age, gender or HIV-RNA between PHI patients who 
returned and those who were lost to follow-up (Supplementary table 2). After one 
month of follow-up, median CD4 T-cell count in PHI-individuals was significantly lower 
10
than in the non-HIV infected group, 585 (IQR 460-682) vs. 955 (IQR 773-1149) cells/uL
respectively (p-value<0.0001); while median CD8 T-cell count was significantly 
higher, 1119 (IQR 741-1650) vs. 591 cells/uL (IQR 417-746) respectively (p-
value<0.0001).
Fiebig staging of PHI patients
The majority of PHI cases (74.1%) was seronegative at presentation (Table 1),
with the remainder indeterminate on rapid tests. Patient HIV-RNA levels at 
presentation were high, with a median of Log10 6.3copies/mL (IQR 5.2-7.3) (Table 1). 
Classification according to Fiebig
14
 revealed that the majority of the 85 PHI cases were 
in Fiebig I-III, 45 (52.9%) whereas 8 (9.4%), 12 (14.1%) and 20 (23.5%) were in Fiebig IV, 
V, and VI respectively. There was no significant difference in age, gender balance or 
initial complaint between Fiebig groups (Table 1). The later Fiebig stages did, however, 
have a higher prevalence of malaria infection (p-value=0.049), and higher rate of 
intestinal complaints in the previous week (p-value=0.010), when compared with the 
earlier stages. As expected, the proportion of PHI cases with an indeterminate result 
for HIV rapid test was significantly higher in Fiebig VI (85%, p-value <0.001) and the 
median HIV-RNA level lower (p-value=0.0001) compared with the earlier Fiebig stages.
Kinetics of subclass HIV-specific humoral responses during PHI
In order to quantify the nascent HIV-specific IgG response by Fiebig stage in our 
cohort, we assessed levels of IgG1, IgG2, IgG3, and IgG4 specific for p24, gp41 and p31 
antigens. The levels of all antibodies against gp41 and p24 detected for subjects in 
Fiebig I-III were similar to those in Fiebig IV. HIV-specific antibody levels significantly
11
increased in Fiebig V and Fiebig VI as compared to Fiebig I-III and IV (Figure 2). As 
expected from WB results, in the case of antibodies against p31 antigen, only the Fiebig
VI group demonstrated significantly higher median level of IgG1 compared with the 
rest of the Fiebig groups (p-value <0.05).
Kinetics of biomarker expression patterns during PHI
From total of 61 biomarkers assessed, 49 were quantifiable in more than 75% of 
the samples and were included for analysis (Supplementary table 1). Besides VL, nine 
biomarkers were differentially expressed across Fiebig groups including total plasma 
IgG, IgG1, sCD163, MCP-1, sCD23, BAFF, MIG, TRAIL and TNFα (p-value<0.1, Figure 3).
Total plasma IgG and IgG1 were highly correlated (Spearman rho=0.78, p-
value<0.0001); thus, only total IgG1 was maintained in subsequent analyses and 8 
biomarkers were then considered differentially expressed. Patients in Fiebig I-III 
showed a significantly different biomarker profile compared with those in Fiebig VI (p-
value<0.01). Levels of total IgG, IgG1, sCD163, sCD23 and MIG significantly increased 
with Fiebig stages, and showed a weak negative correlation with viral load (rho<-0.4 ). 
In contrast, MCP-1, BAFF, TRAIL and INFα biomarkers were expressed at high levels in 
Fiebig I-III and IV stages and decreased in Fiebig V and VI stages, significantly 
correlating with VL levels (p<0.0001, MCP-1 Spearman rho=0.60, BAFF rho=0.60, TRAIL 
rho=0.48 and INFα rho=0.47). There was no significant difference in the plasma level of 
these biomarkers between Fiebig I-III and Fiebig IV or between Fiebig V and Fiebig VI (p-
value>0.05).
Cytokine expression profile can classify primary HIV infection into phases 
12
In order to determine whether the subgroup of eight biomarkers was associated 
with the acute pre-seroconversion stage of the PHI, cases were grouped into two 
categories: 1) the pre-seroconversion acute group roughly covering the 1
st
 month of
PHI (Fiebig I-IV) and 2) the post-seroconversion group referring to recent PHI (Fiebig V-
VI) when HIV-specific antibodies are detectable by Western Blot. 
Random Forest analysis models consistently selected BAFF, MCP-1, sCD163 and
MIG as having the best power to discriminate between the pre and post-
seroconversion phases. Additionally, a biplot representation generated from principal 
component analysis (PCA) showed differential expression patterns for the selected 
biomarkers according to the grouping (Figure 4A). Multivariate regression was 
performed in order to assess the power of the four cytokines to distinguish between 
the two categories (Figure 4B). Based on regression diagnostics measures, five outlier 
observations were excluded from model fitting. Clinical variables (age, gender, VL or 
other co-infection) showed no significant association or interaction with the selected 
biomarkers (data not shown) and were thus eliminated from the model.
BAFF and MCP-1 were positively associated with the pre-seroconversion group 
while sCD163 and MIG were negatively associated (Fig. 4B). The multivariate model 
was capable of correctly identifying 49 out of the 53 individuals in the pre-
seroconversion phase, and 26 out of the 32 in the post-seroconversion phase. This 
goodness of fit allowed the model to identify patients in the pre-seroconversion phase 
with a sensitivity of 92.5% and a specificity of 81.2%.
13
Discussion
This study has identified a signature of four cytokines composed of BAFF, MCP-1, 
sCD163 and MIG that is highly associated with PHI prior to development of the HIV-
specific humoral response as determined by WB
14,15,23
. BAFF and MCP-1 are highly 
expressed in the first month of PHI whereas sCD163 and MIG rise several weeks later. 
Despite roll out of ART and HIV prevention activities, the 3.0% (95% CI 2.4-3.7) 
prevalence of PHI among people presenting with fever-like symptoms at the outpatient 
ward of this rural area of Mozambique has remained unchanged as compared to a 
study performed 5 years earlier which showed an PHI prevalence of 3.3% (95% CI 
1.3–6.7)
21
. Given the high risk of transmission during this phase, these data represent 
an important threat to public health. Periodic cross-sectional PHI screening of people 
presenting with fever like symptoms in malaria-endemic high HIV incidence settings 
could act as an indirect surrogate to monitor evolution of HIV epidemic and compare 
tendencies between different communities or assessing the impact of prevention 
campaigns.
In our cohort of primary HIV infected individuals, the nascent HIV-specific 
antibody response showed a distinct pattern of expression by Fiebig stages.. The 
kinetics of antibody generation during PHI may vary according to individual factors, 
subtype and dose of infecting virus
3
. Previous studies have shown that anti-Env HIV-1 
plasma antibodies are predominantly IgG1 subclass, followed by anti-Env IgG3 subclass
during PHI
24
. Results from our cohort are largely similar. However, very few individuals 
in the earliest Fiebig stages (I-IV) showed positive IgG3 responses to gp41. These 
14
results slightly differ from Yates et al
24,25
 where they found anti-gp41 IgG3 to be 
positive for all PHI individuals.  The timing of detection of antibodies could be 
influenced by the extent of immune complex formation preceding detection of free 
antibody. This could differ by viral load, geographic location or HIV clade. In contrast to 
our Mozambican clade C cohort, their PHI cohort included 37% African individuals 
infected with HIV clade C, which could explain discrepancies. 
In parallel to the stepwise HIV-specific antibody generation, AHI is a period when
many other immune processes are occurring, specifically the innate immune response. 
A general cytokine storm occurring early after HIV infection has described peak levels 
of many inflammatory cytokines prior to seroconversion
18–20,26,27
. In order to fine-tune 
the  immune response pattern, we have assessed those previously described cytokines 
as well as other relevant innate immunity effector molecules. From a total of 49 
analytes that were quantifiable in this cohort, 9 biomarkers demonstrated significant 
difference in the expression level across Fiebig groupings. Furthermore, four of these
biomarkers, BAFF, MCP-1, sCD163 and MIG, exhibited the best predictive power to 
distinguish between individuals in pre and post-seroconversion stages of PHI.
Modelling the expression profile of these four cytokines identified with high sensitivity 
and specificity those individuals in which the antibody generation was still not 
developed. 
Most of the participants (87.1%) were screened for PHI through sampling of 
individuals presenting with febrile syndrome.  While this is the most practical way of 
finding PHI, the cytokine and antibody expression profile in symptomatic individuals 
may not be generalizable to asymptomatic individuals. Although Hepatitis B, syphilis 
15
and intestinal pathogen co-infections were not found to be associated with stage of 
HIV infection or levels of cytokines, we cannot exclude that other infections commonly 
present in HIV-infected individual, could affect plasma levels of these biomarkers.  
Another limitation is the lack of resolution of early Fiebig stages due to sample volume 
restrictions. We cannot exclude that cytokine expression may differ between Fiebig I-
III. A detectable gradient of cytokine expression could become visible particularly in the 
transition through Fiebig III, similar to Fiebig IV. However this would likely maintain or 
even strengthen the signature association.
To our knowledge, no cytokine signature has been previously described to be 
associated with the pre-seroconversion phase of PHI. In our cohort, increased pre-
seroconversion expression of MCP-1 was accompanied by elevated BAFF. In contrast, 
sCD163 and MIG showed a delayed increase during the early infection process which 
paralleled the decrease in BAFF and MCP-1. Monocyte chemotactic protein (MCP-1) 
and B-cell activating factor (BAFF) are both produced by monocytes, macrophages and 
dendritic cells after infection or tissue inflammation in order to assure a proper 
immune response and maintenance of normal immunity
28–30
. In contrast, macrophage 
low-grade inflammation marker (sCD163) and monokine induced by IFN-γ (MIG) are 
cytokines involved in T-cell trafficking to inflammatory sites and control of T-cell 
proliferation
31–33
. Since BAFF and MCP-1 expression is associated with early innate 
responses, they may be the very first effectors in the HIV immune cascade followed 
closely by sCD163 and MIG, associated with the initiation of adaptive immune 
responses. Further studies including gut biopsies in humans or non-human primates 
may show whether BAFF and MCP-1 expression are associated with viral shedding or 
16
early HIV-induced GALT destruction.
There is an interest in approaching AHI as a phase of infection in which early ART 
coupled with adjunct targeted immune therapy could limit the destruction of the 
mucosal lymphoid tissue and seeding of the HIV reservoir. Approaches include boosting 
HIV-specific immunity, reducing inflammation, activating latency and targeting HIV 
apoptosis regulatory pathways
7,34–36
. Recent studies also point out that cART initiated 
during early AHI either prevents loss of (at Fiebig stage I/II) or restores (at Fiebig stage 
III) mucosal Th17 cells
37
.  Consequently, very early ART is associated with normalization 
of local and systemic immune activation, reversing a hallmark of HIV pathogenesis
37
.
Although further analysis will be required to define whether there is a causal 
relationship between BAFF and MCP-1 expression and antibody generation, these 
cytokines might be potential targets to boost the humoral response in vaccination 
strategies or to accelerate the HIV-specific antibody response during PHI. Modulation 
of these cytokines might promote an earlier development of autologous neutralizing 
antibodies that may contribute to faster and long lasting control of HIV
38,39
.
17
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FIGURE LEGENDS
Figure 1: Screening profile: VL=viral load, WB=Western Blot test, Sympt.=symptomatic 
patients, VCT=patients presented for voluntary counselling and testing. *Study protocol 
was changed to include rapid test indeterminate patients, however four individuals 
were excluded prior to this change. 
Figure 2. HIV-specific antibody expression according to Fiebig stage.  The median MFI 
(mean fluoresence intensity) is shown for antibodies specific for A) gp41, B) p24 and C) 
p31. Box as IQR, middle line as median, whiskers as Tukey values (1.5 IQR). Values are 
Log10 scale for a better adjustment of the data. Nonparametric pairwise multiple 
comparisons were performed by using Dunn’s test. Bonferroni-adjusted significance is 
indicated as *** if p<0.001, ** if p<0.01 and * if p<0.05. Median values for the non-
febrile non-HIV infected reference group are indicated as dotted lines.
Figure 3. Expression of selected parameters varies by Fiebig stage. Nine biomarkers 
were differentially expressed across Fiebig groups including total plasma IgG, IgG1, 
sCD163, MCP1, sCD23, BAFF, MIG, TRAIL and TNFα (p-value<0.1), as was VL (p-
value<0.001) by Kruskall-Wallis range comparison (Bonferroni adjusted p-value <0.01). 
Median levels of selected parameters are represented as middle line, box as IQR and 
whiskers as Tukey values (1.5 IQR). Comparison of individual difference in expression 
level by Fiebig group was performed by Dunn’s comparison test adjusted by Bonferroni
for multiple comparisons as shown above. Significance is indicated as *** if p<0.001, ** 
if p<0.01 and * if p<0.05. Median values for the non-febrile non-HIV infected reference 
23
group are indicated as dotted lines.
Figure 4. Cytokines with best discriminatory power to differentiate between early 
and late Fiebig stages.  A. Component analysis of cytokine levels. Principal component 
analysis of BAFF, MCP-1, MIG and sCD163 levels in patients in pre- or post- 
seroconversion stages (Fiebig I-IV, Fiebig V-VI respectively). B. Multivariate logistic-
regression to identify cytokines associated with pre-seroconversion stage of HIV 
infection (Fiebig I-IV). Significance of the variable in the model is indicated as ** if 
p<0.01 and * if p<0.05. In both PCA and regression model, MIG, MCP1 and BAFF values 
were log transformed for a better adjustment of the data.
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1Table 1. Clinic and demographic characteristics of study population according to HIV-status and Fiebig stage. Comparisons for proportions were 
performed by chi2 testᵡ and continuous variables by Mann and Whitney U-test* for the two group comparison and global comparison by Kruskal
Wallis test**. p-value obtained from (1) comparison by study group or (2) comparison by Fiebig group.
HIV-neg at 
Screening 
(n=3019)
PHI at 
Screening 
(n=85)
p-value 
1
Fiebig I-III 
(n=45)
Fiebig IV 
(n=8)
Fiebig V 
(n=12)
Fiebig VI 
(n=20)
p-value 
2
Age (years) [Median (IQR)] 26 (20-35) 24 (20-30) 0.083* 23 (19-32) 25 (20-35) 23 (19-31) 26 (20-28) 0.8994**
Gender [F (%)] 1900 (63) 50 (58) 0.441ᵡ 28 (62) 3 (37) 8 (67) 11 (55) 0.543ᵡ
Initial complaint [n (%)] 
Headache                          
Febrile syndrome    
Flu symptoms             
Voluntary testing             
Others  
80 (3)               
2385 (79)             
153 (5)               
395 (13)                           
6 (0)
1 (1)               
75 (88)               
6 (7)                   
3 (4)                
0 (0)
0.401ᵡ                
0.039ᵡ                  
0.412ᵡ                  
0.010ᵡ                  
1ᵡ
1 (2)              
41 (91)             
2 (4)                
1 (2)              
0 (0)
0 (0)                  
8 (100)               
0 (0)                   
0 (0)                 
0 (0)
0 (0)                
11 (92)               
0 (0)                
1 (8)                
0 (0)
0 (0)                
15 (75)              
4 (20)             
1 (5)                
0 (0)
0.395ᵡ
Fever last 24h [n (%)] 2503 (83) 80 (94) 0.024ᵡ 43 (96) 8 (100) 11 (91) 18 (90) 0.703ᵡ
Malaria [n (%)] 337 (17) 7 (11) 0.234ᵡ 1 (3) 0 (0) 3 (33) 3 (17) 0.049ᵡ
Intestinal complaint last 
week [n (%)]
84 (3) 9 (11) < 0.001ᵡ 1 (2) 1 (12) 1 (8) 6 (30) 0.010ᵡ
RT Serostatus [n (%)]    
Negative                       
Indeterminate
- 63 (74)          
22 (26)
- 44 (98)           
1 (2)
8 (100)           
0 (0)
8 (67)             
4 (33)
3 (15)            
17 (85)
< 0.001ᵡ
Viral Load (RNA Log 10 
copies/mL) [Median (IQR)]
- 6.3 (5.2-7.3) - 7.1 (6.2-7.5) 7.0 (6.3-7.4) 5.6 (4.9-6.3) 4.8 (4.3-5.5) 0.0001**
Europe PMC plus has received the file 'Supplementary data_LuciaPastor.docx' as 
supplementary data. The file will not appear in this PDF Receipt, but it will be linked to the 
web version of your manuscript. 
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